CapWealth Advisors LLC Cuts Stake in Johnson & Johnson (NYSE:JNJ)

CapWealth Advisors LLC lowered its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 0.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 139,567 shares of the company’s stock after selling 429 shares during the quarter. Johnson & Johnson makes up 2.7% of CapWealth Advisors LLC’s portfolio, making the stock its 14th biggest holding. CapWealth Advisors LLC’s holdings in Johnson & Johnson were worth $21,876,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Bond & Devick Financial Network Inc. grew its holdings in Johnson & Johnson by 6.4% during the 3rd quarter. Bond & Devick Financial Network Inc. now owns 6,531 shares of the company’s stock valued at $1,017,000 after buying an additional 393 shares in the last quarter. Worth Financial Advisory Group LLC grew its holdings in Johnson & Johnson by 4.9% during the 3rd quarter. Worth Financial Advisory Group LLC now owns 11,537 shares of the company’s stock valued at $1,797,000 after buying an additional 542 shares in the last quarter. Ritholtz Wealth Management grew its holdings in Johnson & Johnson by 90.9% during the 3rd quarter. Ritholtz Wealth Management now owns 41,394 shares of the company’s stock valued at $6,447,000 after buying an additional 19,714 shares in the last quarter. Arkadios Wealth Advisors grew its holdings in Johnson & Johnson by 54.3% during the 3rd quarter. Arkadios Wealth Advisors now owns 71,925 shares of the company’s stock valued at $11,202,000 after buying an additional 25,298 shares in the last quarter. Finally, Venture Visionary Partners LLC boosted its holdings in shares of Johnson & Johnson by 0.4% in the 3rd quarter. Venture Visionary Partners LLC now owns 99,877 shares of the company’s stock worth $15,558,000 after purchasing an additional 373 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insiders Place Their Bets

In related news, EVP Jennifer L. Taubert sold 59,397 shares of the company’s stock in a transaction on Friday, February 9th. The stock was sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the completion of the sale, the executive vice president now directly owns 141,416 shares in the company, valued at approximately $22,099,078.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, major shareholder & Johnson Johnson sold 3,725 shares of the company’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the sale, the insider now directly owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Jennifer L. Taubert sold 59,397 shares of the company’s stock in a transaction on Friday, February 9th. The stock was sold at an average price of $156.27, for a total value of $9,281,969.19. Following the sale, the executive vice president now owns 141,416 shares of the company’s stock, valued at $22,099,078.32. The disclosure for this sale can be found here. Company insiders own 0.16% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on JNJ. Bank of America cut their target price on Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 17th. Royal Bank of Canada cut their target price on Johnson & Johnson from $181.00 to $175.00 and set an “outperform” rating on the stock in a research report on Wednesday, April 17th. Morgan Stanley cut their target price on Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating on the stock in a research report on Wednesday, April 17th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, February 6th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a research report on Monday, April 15th. Seven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $175.86.

Johnson & Johnson Price Performance

JNJ opened at $149.56 on Wednesday. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $175.97. The stock has a market cap of $360.41 billion, a P/E ratio of 9.32, a PEG ratio of 2.44 and a beta of 0.53. The business has a fifty day moving average of $155.83 and a 200 day moving average of $155.51. The company has a quick ratio of 0.91, a current ratio of 1.16 and a debt-to-equity ratio of 0.38.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, topping the consensus estimate of $2.64 by $0.07. Johnson & Johnson had a return on equity of 36.43% and a net margin of 45.26%. The business had revenue of $21.38 billion during the quarter, compared to analysts’ expectations of $21.39 billion. During the same period in the prior year, the business earned $2.68 EPS. The business’s revenue for the quarter was up 2.3% compared to the same quarter last year. As a group, sell-side analysts anticipate that Johnson & Johnson will post 10.65 EPS for the current year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Tuesday, May 21st will be issued a $1.24 dividend. This represents a $4.96 annualized dividend and a dividend yield of 3.32%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.19. The ex-dividend date of this dividend is Monday, May 20th. Johnson & Johnson’s dividend payout ratio is currently 30.92%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.